Anavex Life Sciences (AVXL) Interest Expenses (2010 - 2025)
Anavex Life Sciences (AVXL) posted Interest Expenses of $2.5 billion for Q4 2025, down 93.58% sequentially from $39.7 billion in Q3 2025, and up 3589.52% YoY from $69.1 million in Q4 2024.
Anavex Life Sciences (AVXL) Interest Expenses (2010 - 2025) Analysis & Trends
Anavex Life Sciences has reported Interest Expenses for 16 years, with the latest figure at $2.5 billion in Q4 2025.
- Quarterly Interest Expenses rose 3589.52% year-over-year to $2.5 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 billion (up 3589.52% YoY) and the FY2025 annual result came in at $39.7 billion, up 42960.08% from the prior year.
- Interest Expenses eased to $2.5 billion in Q4 2025 per AVXL's latest filing, from $39.7 billion in the prior quarter.
- Over five years, Interest Expenses peaked at $39.7 billion in Q3 2025 and troughed at $7.5 million in Q2 2024.
- A 5-year average of $2.2 billion and a median of $60.5 million in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses plunged 80.88% in 2024, then soared 42960.08% in 2025.
- Over 5 years, Interest Expenses stood at $132.0 million in 2021, then plunged by 61.61% to $50.7 million in 2022, then slipped by 5.93% to $47.7 million in 2023, then soared by 44.96% to $69.1 million in 2024, then jumped by 3589.52% to $2.5 billion in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $2.5 billion, $39.7 billion, and $45.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.55 Bn |
| Dec 31, 2025 | 2.55 Bn |
| Sep 30, 2025 | 39.72 Bn |
| Sep 30, 2025 | 39.72 Bn |
| Jun 30, 2025 | 45.81 Mn |
| Jun 30, 2025 | 45.81 Mn |
| Mar 31, 2025 | 38.63 Mn |
| Mar 31, 2025 | 38.63 Mn |
| Dec 31, 2024 | 69.11 Mn |
| Dec 31, 2024 | 69.11 Mn |
| Sep 30, 2024 | 92.23 Mn |
| Sep 30, 2024 | 92.23 Mn |
| Jun 30, 2024 | 7.47 Mn |
| Jun 30, 2024 | 7.47 Mn |
| Mar 31, 2024 | 12.48 Mn |
| Mar 31, 2024 | 12.48 Mn |
| Dec 31, 2023 | 47.67 Mn |
| Dec 31, 2023 | 47.67 Mn |
| Sep 30, 2023 | 22.29 Mn |
| Sep 30, 2023 | 22.29 Mn |